Incretin-based therapies: where will we be 50 years from now? (Q39004418)

8 September 2017

Incretin-based therapies: where will we be 50 years from now? (English)

1 reference

8 September 2017

Juris J Meier

1

1 reference

PubMed ID

25994073

8 September 2017

Michael A Nauck

series ordinal

2

1 reference

8 September 2017

21 May 2015

1 reference

8 September 2017

1 reference

8 September 2017

58

1 reference

8 September 2017

1745-1750

1 reference

8 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-015-3608-6

8 September 2017

0 references

cites work

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

GIP as a potential therapeutic agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Bariatric surgery versus conventional medical therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Cardiovascular actions of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Exenatide and the treatment of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3608-6

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25994073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-015-3608-6

1 reference

8 September 2017

1 reference

PubMed ID

25994073